FDA Announcement and Implementation Dates
The FDA’s CDER and CBER announced that CDISC SDTM v1.7 and Define‑XML 2.1 become mandatory on 01/01/2027. The notice‚ issued 08/28/2026‚ grants sponsors a six‑month transition period to comply with the new standards. Sponsors must submit all datasets by 01/01/2028 to avoid penalties.Soon! OK
CDER and CBER Guidelines for SDTM IG 3.3
Define‑XML 2.1 Release Schedule
Overview of SDTM Implementation Guide v3.3
The SDTMIG v3.3 offers a detailed guide for human clinical trials‚ covering domain structures‚ variable naming‚ value sets‚ and metadata. It introduces new domains‚ clarifies assumptions‚ and aligns with Define‑XML 2.1 for seamless data exchange‚ ensuring full compliance with FDA standards for review
Purpose and Scope of SDTMIG v3.3
Key Features of SDTMIG v3.3
SDTMIG v3.3 introduces a range of enhancements that streamline data submission and improve regulatory review. Key features include the addition of new domains—Morphology (MORPH)‚ Physiology (PHYS)‚ and Biomarker (BMD)—which capture detailed tissue and functional data. The guide refines Disposition (DS) assumptions‚ providing clearer rules for handling missing or ambiguous data points.
Variable naming conventions are expanded to support longer‚ more descriptive labels while maintaining compatibility with existing CDISC standards. Value code tables are updated to include additional clinical codes‚ including SNOMED CT and LOINC extensions‚ ensuring precise representation of observations across studies.
Metadata requirements are tightened‚ with mandatory Define‑XML 2.1 elements that describe dataset structure‚ variable definitions‚ and coding systems. The IG also introduces a new validation framework that integrates with the CDISC Data Standards Validation Tool‚ enabling automated checks for syntax‚ consistency‚ and completeness.
The validation framework supports cross‑domain consistency checks‚ such as ensuring that subject identifiers match across all datasets and that timing variables align with protocol‑defined visit schedules. It also validates that value codes are present in the approved reference tables.
Guidance on mapping legacy data to the new model is provided‚ reducing transition effort for sponsors. Overall‚ these features support more accurate‚ interoperable‚ and regulatory‑ready data submissions‚ facilitating faster review cycles and improving data integrity for human clinical trials.
Structure of SDTM IG v3.3
SDTMIG v3.3 is organized into three core sections: the Reference Guide‚ the Implementation Guide‚ and the Validation Guide. Each section contains domain definitions‚ variable specifications‚ and coding tables‚ all linked via Define‑XML 2.1 metadata for seamless integration. The guide ensures!!
Standard Domains Covered in SDTM v3.3
SDTMIG v3.3 expands the core domain set to support the latest regulatory requirements and emerging data types. The standard domains now include the foundational AD (Adverse Events)‚ AE (Adverse Events)‚ CM (Concomitant Medications)‚ DS (Disposition)‚ DM (Demographics)‚ EX (Exposures)‚ LB (Laboratory)‚ ME (Medical History)‚ MH (Medical History)‚ NE (Neurological Examination)‚ PE (Physical Examination)‚ PG (Pharmacogenomics)‚ PT (Physiotherapy)‚ RE (Radiology)‚ SC (Screening)‚ SM (Subject Medical History)‚ SR (Study Report)‚ TR (Treatment)‚ VR (Vital Signs)‚ and XS (Miscellaneous). Each domain is defined with a consistent set of variables‚ naming conventions‚ and value codes‚ ensuring interoperability across submissions. In addition to the core domains‚ v3.3 introduces the MO (Morphology) and PH (Physiology) domains‚ which capture detailed tumor morphology and organ physiology data‚ respectively. These new domains are designed to accommodate oncology and translational research studies that require granular biological descriptors. The guide also provides optional domains such as AL (Adverse Event Lab)‚ AP (Adverse Event Pathology)‚ and AT (Adverse Event Treatment) for studies that collect additional context around adverse events. All domains are accompanied by detailed variable descriptions‚ permissible values‚ and coding references‚ enabling data submitters to map raw data accurately to the SDTM structure. The inclusion of these domains reflects the FDA’s commitment to harmonizing data capture across therapeutic areas while maintaining rigorous data quality standards.
Variable Naming Conventions and Value Codes
SDTMIG v3.3 enforces a strict 8‑character variable name rule‚ where the first two letters designate the domain and the remaining six letters describe the variable. For example‚ DSSTDTC (Disposition Start Date/Time) and LBTESTCD (Laboratory Test Code) follow this pattern. Variable names must be uppercase‚ alphanumeric‚ and may not contain spaces or special characters. The guide specifies a set of permissible value codes for each variable; these codes are drawn from controlled vocabularies such as MedDRA for adverse events‚ WHO Drug for medications‚ and LOINC for laboratory tests. When a variable accepts a numeric code‚ the SDTMIG provides a lookup table mapping the code to its descriptive label. For instance‚ the DSSTDTC variable uses a date/time format of YYYY-MM-DDTHH:MM:SS with a “Z” suffix for UTC. Value codes for categorical variables are defined in the SDTM Value Set tables‚ which include codes for “Yes”‚ “No”‚ “Unknown”‚ and “Not Applicable”. The guide also introduces the SDTM Value Set for new domains such as Morphology (MO) and Physiology (PH)‚ ensuring consistent coding across studies. All value codes are case‑insensitive and must be validated against the official CDISC value set repositories. The implementation guide recommends using the CDISC Value Set API for automated validation during data preparation. In summary‚ strict adherence to naming conventions and value code standards guarantees data integrity‚ facilitates regulatory review‚ and supports cross‑study data integration. The SDTMIG v3.3 also stresses the need for a consistent data dictionary‚ the use of the CDISC Value Set API for code validation‚ and recommends sponsors perform thorough data checks before submission to meet FDA expectations and ease regulatory review before submission.?!
Enhancements and Revisions in SDTM IG v3.3
SDTMIG v3.3 introduces revised disposition assumptions‚ new morphology and physiology domains‚ expanded value sets‚ enhanced variable naming guidance‚ and updated timing variables. These changes improve clarity‚ consistency‚ and regulatory compliance for human trials; All updates align CDISC!!
Revised Disposition (DS) Assumptions
Revised Disposition (DS) assumptions in SDTMIG v3.3 clarify how to capture and report subject disposition events‚ ensuring consistency across studies. The updated guidance defines a standardized set of disposition codes‚ including new codes for partial withdrawals‚ protocol deviations‚ and post‑study follow‑ups. It introduces a hierarchical structure for DS events‚ allowing multiple related events to be linked to a single subject visit. The revised model also expands the timing variables‚ adding a DS‑START and DS‑END date/time fields to capture the exact window of each disposition event. Additionally‚ the guidance now requires a DS‑REASON variable that captures the clinical or administrative reason for the disposition‚ with a controlled vocabulary to improve data quality. The updated DS assumptions include explicit rules for handling missing or incomplete disposition data‚ providing a default value and validation checks. These enhancements aim to reduce ambiguity‚ improve audit trail transparency‚ and facilitate regulatory review by providing a clear‚ standardized framework for reporting subject disposition across all phases of a clinical trial.
- DS‑START and DS‑END now mandatory for all disposition events.
- DS‑REASON uses controlled vocabulary with 200+ codes.
- Hierarchical DS events allow linking of related withdrawals to a single visit.
- Validation rules enforce completeness and flag missing DS data.
These updates streamline‚ times‚ enhance consistency quickly fast;
SDTMIG v3.3 introduces two new domains—Morphology (MOR) and Physiology (PHY)—to capture detailed anatomical and functional data that were previously scattered across multiple custom datasets. The MOR domain records biopsy‚ imaging‚ and histopathology findings‚ including specimen type‚ site‚ and diagnostic codes‚ using a standardized set of value codes aligned with the Common Data Elements (CDE) framework. The PHY domain captures physiological measurements such as heart rate‚ blood pressure‚ pulmonary function‚ and metabolic parameters‚ providing a structured format for time‑pointed observations. Both domains include mandatory timing variables (START‚ END‚ and VISIT) and a standardized set of value qualifiers (e;g.‚ NORMAL‚ ABNORMAL‚ INCONCLUSIVE) to facilitate consistent interpretation across studies. The new domains are designed to support regulatory submissions by ensuring that critical morphological and physiological data are reported in a uniform‚ machine‑readable format‚ thereby reducing the need for manual data reconciliation. They also enable advanced analytics‚ such as correlating tissue pathology with systemic biomarkers‚ by linking MOR and PHY records to core domains through the global subject identifier (USUBJID) and visit identifiers (VISITNUM). The implementation guidance provides detailed variable definitions‚ coding rules‚ and example datasets to help sponsors adopt the domains efficiently. By integrating MOR and PHY into the SDTM framework‚ the guide enhances data transparency‚ supports cross‑study comparisons‚ and aligns with emerging precision medicine initiatives that emphasize tissue‑based and functional endpoints. This addition reflects the FDA’s commitment to modernizing data standards to accommodate evolving clinical trial designs and endpoints.!!!
Download and Format Options for SDTM IG v3.3
PDF Version of the IG
The PDF version of the SDTM Implementation Guide (IG) version 3.3 is the definitive‚ fully formatted reference for regulatory submissions. It is a single‚ searchable PDF file that can be opened with any standard PDF reader‚ including Adobe Acrobat Reader‚ Foxit Reader‚ or the built‑in viewer in most web browsers. The document is 120 pages long and contains a complete table of contents‚ index‚ and cross‑referenced glossary. Each domain is presented on a separate page with a consistent layout that includes a domain header‚ variable list‚ and value code table. The PDF is optimized for printing; margins are set to 1.5 inches on all sides‚ and the font is Times New Roman 10pt for body text and 12pt for headings. The file size is approximately 4.2 MB‚ making it easy to download and share via email or cloud storage. The PDF includes embedded hyperlinks that allow users to jump directly to the definition of a variable or to the related value code. It also contains a “Search” function that can be accessed by pressing Ctrl + F‚ which highlights all occurrences of a term. The PDF is available for free download from the CDISC website under the “Resources” section‚ specifically the “SDTM IG v3.3” page. Users can click the “Download PDF” button‚ which initiates a direct download of the file. The PDF is the preferred format for regulatory submissions because it preserves formatting and is accepted by the FDA’s electronic submission system‚ eCTD. The PDF is 4.2 MB‚ free. The PDF supports version control metadata.!
The HTML version of the SDTM Implementation Guide (IG) v3.3 is a web‑based‚ fully interactive representation of the standard. It is hosted on the CDISC website and can be accessed directly in any modern browser. The guide is structured into a series of linked sections‚ each corresponding to a domain or a set of related domains. Navigation is facilitated by a persistent sidebar that contains a collapsible table of contents‚ allowing users to jump directly to the domain of interest. Each domain page includes a concise summary‚ a detailed variable list‚ and a value‑code table. Hyperlinks within the variable list lead to the variable’s definition and to the associated value‑code table‚ while value codes are linked to their full descriptions. The HTML format supports responsive design‚ ensuring readability on both desktop and mobile devices. A built‑in search box at the top of the page allows quick access to specific variables or terms. The HTML files are available for download as a ZIP archive containing all HTML pages‚ CSS stylesheets‚ and supporting images. The ZIP package is approximately 2.5 MB. The HTML version is ideal for training‚ quick reference‚ and for developers who wish to embed the guide into internal documentation systems. It is also accepted by the FDA’s eCTD system for electronic submissions‚ provided the HTML files are packaged correctly. The HTML version is free to download from the CDISC “Resources” section‚ specifically the “SDTM IG v3.3” page. The HTML version is 2.5 MB‚ free. The HTML guide is version‑controlled; each update to the PDF is mirrored in the HTML‚ ensuring consistency across formats. The guide includes a change‑log page that lists all revisions‚ dates‚ and authors‚ making it easy to track the evolution of the standard. Users can also subscribe to the CDISC RSS feed to receive notifications of new releases. The HTML pages are encoded in UTF‑8 and use semantic HTML5 elements‚ which improves accessibility for screen readers and other assistive technologies. The guide also includes downloadable CSV templates for each domain‚ which can be used to validate data before submission. Finally‚ the HTML version is indexed by search engines‚ allowing users to find specific terms quickly via Google or internal search tools.
